René S. Kahn, MD, PhD

  • 11Articles
  • 63.2KReads
  • 2007–2024Active
  • 52Collaborators
  • 784Citations

About

René S. Kahn, MD, PhD, is affiliated with the Department of Psychiatry and Behavioral Health System at the Icahn School of Medicine at Mount Sinai in New York. Since 2007, Kahn has published extensively on schizophrenia, schizoaffective disorders, bipolar disorder, and weight-related issues. His work includes studies on antipsychotic treatments such as olanzapine and samidorphan, the efficacy of nonsteroidal anti-inflammatory drugs in schizophrenia, and interventions for auditory hallucinations. Kahn frequently collaborates with Christina Arevalo, Christoph U. Correll, David McDonnell, Eske M. Derks, and Iris E. Sommer.

Publications

JCP
Long-Term Safety and Treatment Effect of Olanzapine/Samidorphan
Original Research

Long-Term Safety and Treatment Effect of Olanzapine/Samidorphan

December 4, 2024

During up to 4 years of treatment, the combination of olanzapine/samidorphan was safe and well-tolerated, and patients’ symptoms remained stable.
, , , et al
JCP
Generalizability of RCTs in First-Episode Schizophrenia
Original Research

Generalizability of RCTs in First-Episode Schizophrenia

March 29, 2023

First-episode schizophrenia patients with suicidal ideation and substance use disorder are often excluded from clinical trials. Omitting them does not affect key outcome measures but excludes many potential subjects.
, , , et al
JCP
Olanzapine/Samidorphan Mitigates Weight Gain in Early Illness
Original Research

Olanzapine/Samidorphan Mitigates Weight Gain in Early Illness

March 22, 2023

In patients with early-phase schizophrenia or bipolar disorder, combination olanzapine and samidorphan resulted in less weight gain at week 12 than olanzapine alone. Antipsychotic efficacy was similar between the...
, , , et al
JCP
Review Article

Nonsteroidal Anti-Inflammatory Drugs in Schizophrenia: Ready for Practice or a Good Start? A Meta-Analysis

December 13, 2011

, , , et al
JCP
Original Research

Efficacy of Antipsychotic Drugs Against Hostility in the European First-Episode Schizophrenia Trial (EUFEST)

July 15, 2011

, , , et al
JCP
Original Research

The Same or Different? A Phenomenological Comparison of Auditory Verbal Hallucinations in Healthy and Psychotic Individuals

March 15, 2011

, , , et al
JCP
Original Research

Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders: Results From a Randomized, Double-Blind, Placebo-Controlled Trial

May 15, 2010

, , , et al
JCP
Original Research

Hippocampal Volume Change in Schizophrenia

January 12, 2010

, , , et al
JCP
Original Research

Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparisons Between Subgroups of Participants of the European First Episode Schizophrenia Trial (EUFEST)

October 20, 2009

, , , et al
JCP
Original Research

Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Acute Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study

June 15, 2007

, , , et al
JCP
Original Research

Efficacy of Slow Repetitive Transcranial Magnetic Stimulation in the Treatment of Resistant Auditory Hallucinations in Schizophrenia: A Meta-Analysis

March 15, 2007

, ,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe